| 프로젝트 이름 | 프로젝트 단계 | 분자 유형 | 분자 출처 | 질병 영역 | 적응증 |
|---|---|---|---|---|---|
| EpCAM CAR-T -01 | IIT | CAR | Humanized Mouse | Solid Tumor | Gastric Cancer |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Recombinant Anti-EpCAM and Anti-CD3Human-mouse Chimeric Bispecific Antibody for Injection (Wuhan Yzy Biopharma Co Ltd) | M-701 | Phase 3 Clinical | Wuhan Yzy Biopharma Co Ltd | Ascites; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hydrothorax; Neoplasms; Ovarian Neoplasms; Pleural Effusion, Malignant; Solid tumours; Stomach Neoplasms | 상세 |
| Oportuzumab monatox | 4D5MOCB-ETA; VB4-845; VB-4847; B-4845; VB-845 | Phase 3 Clinical | Sesen Bio Inc, Viventia Biotech Inc | Carcinoma, Squamous Cell; Head and Neck Neoplasms; Mouth Neoplasms; Neoplasms, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | 상세 |
| Anti-EPCAM CAR-T cell therapy (Sinobioway) | Phase 2 Clinical | Beijing Sinobioway Bioengineering Group Co Ltd | Liver Neoplasms; Stomach Neoplasms | 상세 | |
| DuoBody-EpCAMx4-1BB | BNT314/GEN1059; GEN-1059; GEN1059; BNT314 | Phase 2 Clinical | Biontech Se, Genmab A/S | Colorectal Neoplasms; Neoplasms; Solid tumours | 상세 |
| IMC-001(Immunofoco) | IMC001; IMC-001 | Phase 2 Clinical | Suzhou Immunofoco Biotechnology Co Ltd | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | 상세 |
| BA-3182 | BA-3182 | Phase 1 Clinical | Bioatla | Adenocarcinoma; Solid tumours | 상세 |
| KK-2269 | KK-2269; KK2269 | Phase 1 Clinical | Kyowa Kirin Inc | Carcinoma, Non-Small-Cell Lung; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | 상세 |
| AM-928 | AM-928 | Phase 1 Clinical | AcadeMab Biomedical Inc | Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours; Thyroid Carcinoma, Anaplastic | 상세 |
| Varsetatug masetecan | CX-2051; Varseta-M | Phase 1 Clinical | Cytomx Therapeutics Inc, Immunogen Inc | Colorectal Neoplasms; Neoplasms; Solid tumours | 상세 |
| 99mTc-HE3-G3 | 99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3; 99mTc-(CO)3-(HE)3-Ec1; [99mTc]Tc(CO)3-(HE)3-Ec1 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms; Solid tumours | 상세 |
| A-337 | A-337 | Phase 1 Clinical | Evive Biotech Ltd | Neoplasms; Solid tumours | 상세 |
| PMC2129G12 | PMC2129G12 | Forevertech Biotechnologies Co Ltd | 상세 |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 가장 빠른 브랜드 이름 | 가장 빠른 승인 국가 | 가장 빠른 적응증 | 가장 빠른 승인 회사 | 가장 빠른 승인 날짜 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|---|---|---|---|---|
| Catumaxomab | LP000 | Approved | Neovii Biotech Gmbh, Trion Research | Removab, Korjuny | EU | Ascites | Lindis Biotech GmbH | 2009-04-20 | Ascites; Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | 상세 |


